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Abstract
Background:  The aim of this study was to identify and compare factors associated with
Plasmodium falciparum gametocyte carriage in three regions of differing malaria endemicity.
Methods: Retrospective data from Thailand, The Gambia and Tanzania were used. The data came
from large prospective field-based clinical trials, which investigated gametocyte carriage after
different anti-malarial drug treatments.
Results: Gametocytaemia was detected during the observation period in 12% of patients (931 out
of 7548) in Thailand, 34% (683 out of 2020) in The Gambia, and 31% (430 out of 1400) in Tanzania
(p < 0.001). Approximately one third (33%, 680/2044) of the patients with gametocytaemia during
the observation period, already had patent gametocytaemia at enrolment (day 0 or day 1): 35%
(318/931) in Thailand, 37% (250/683) in The Gambia, 26% (112/430) in Tanzania. Maximum
gametocytaemia was usually observed on or before the seventh day after starting treatment (93%
in Thailand, 70% in Tanzania and 78% in The Gambia). Lowest gametocyte carriage rates were
observed following treatment with artemisinin derivatives, while sulphadoxine-pyrimethamine (SP)
was associated with significantly greater development of gametocytaemia than other drug
treatments (p < 0.001). The duration of gametocyte carriage was shorter in Thailand by 86% and
Tanzania by 65% than in The Gambia. Gametocyte carriage was 27% longer among people
presenting with anaemia, and was shorter in duration among patients who received artemisinin
derivatives, by 27% in Thailand and by 71% in Tanzania and The Gambia.
Conclusion: This study confirms the independent association of gametocytaemia with anaemia,
and the significantly lower prevalence and duration of gametocyte carriage following treatment with
an artemisinin derivative. The large differences in gametocyte carriage rates between regions with
different levels of malaria transmission suggest that drug interventions to prevent transmission will
have different effects in different places.
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Background
Malaria control rests traditionally on two strategies; vector
control (reducing the numbers of anopheline vectors and
reducing the probability of being bitten), and drug treat-
ment. Effective anti-malarials reduce morbidity, prevent
mortality, and reduce asexual parasite biomass. This, in
turn, reduces the numbers of sexual (transmissible) para-
sites (gametocytes). In Plasmodium falciparum infections, it
remains unclear whether gametocyte production is pro-
grammed early on after hepatic schizogony or is a
response to stimuli acting upon the parasite population.
The proportion of parasites committed to sexual stage
development may change during the course of an infec-
tion. The developing sexual stages (stages I to IV) remain
sequestered in the microvasculature for approximately 10
days before appearing as morphologically distinct male
and female stage V gametocytes in the peripheral blood.
One male (containing eight microgametes) and one
female (macro-gamete) are required per mosquito blood
meal (approx 2 μL) for infection to occur. Thus gameto-
cyte densities of 1 per μL are theoretically sufficient to
infect mosquitoes, a density beneath the limit of detection
for most routine microscopy. This explains malaria trans-
mission from subjects without apparent gametocytaemia.
In areas of low or unstable transmission most malaria
infections are transmitted by people who are ill, or recov-
ering from symptomatic malaria. In such areas asympto-
matic infections are unusual, so treatment-seeking
behaviour and the pharmacokinetic and pharmacody-
namic properties of the anti-malarial drugs used are
important determinants of transmission. But low trans-
mission settings often contain small foci of higher trans-
mission and the few asymptomatic individuals in these
areas are important in sustaining malaria through the dry
season. In higher transmission settings the situation is
more complex. Anti-disease controlling immunity is
acquired which results in an increasing proportion of
infections stabilizing at relatively high parasite densities.
These may be either asymptomatic or tolerated in older
patients who are less likely to seek treatment. These infec-
tions may still be transmissible [1]. In addition to immu-
nity against asexual stages there is the development of a
specific immunity against sexual stage parasites which can
further reduce the transmission probability per infection
[2,3]. Several investigators have assessed the contribu-
tions of different age and patient groups to overall malaria
transmission in endemic areas by direct measurement of
infectivity to vector mosquitoes. These studies, which
have been conducted in different geographic regions with
differing patterns of malaria epidemiology, emphasize the
importance of older often asymptomatic individuals in
sustaining transmission of both falciparum and vivax
malaria despite usually lower parasite densities [4-10].
Recrudescence (treatment failure), and the subsequent
extended duration of infection is an important source of
transmission particularly of drug-resistant parasite geno-
types [11]. The factors associated with gametocytogenesis
include the parasite density itself [12,13], anaemia [14],
the duration of infection, stresses on the parasite popula-
tion such as host immunity (related to age) or anti-malar-
ial treatment, and the stage specificity of the anti-malarial
drugs used. The relationship between gametocyte density
in blood and the transmission probability is generally sig-
moid [15-17], although it varies between individuals and
is affected by the factors described above [18,19].
The aim of this study was to identify factors associated
with gametocyte carriage at different levels of malaria
transmission and thus clinical epidemiology. Retrospec-
tive data from study sites in three different endemic areas
were used. The data come from large prospective field-
based clinical trials which investigated gametocyte car-
riage after different anti-malarial drug treatments.
Methods
Description of study sites
Tanzania
The Tanzanian studies were carried out near Ifakara, in the
Kilombero district in the southeast of the country between
1997 and 1999. At the time falciparum malaria was the
foremost health problem in the district. In a one-year
period, 37% of children (aged 0–15) admitted to hospital
in Ifakara were diagnosed as having malaria with a case
fatality rate of 3% [20]. Most of these were infants. At the
time these data were collected, the parasite prevalence in
rural areas was approximately 70%, rising to 90% in chil-
dren under five years, and remained high all year-round.
Nearly all these cases were P. falciparum, although Plasmo-
dium malariae and  Plasmodium ovale infections also
occurred occasionally. Entomological inoculation rates
(EIRs) were between 200 and 300 infective bites per per-
son per year, with no seasonal variation. In this region,
there were a large number of government dispensaries
and chloroquine was widely available in local shops. This
study on gametocyte dynamics was part of a larger study
investigating natural transmission-blocking immunity in
this area of intense perennial transmission [21].
The Gambia
The Gambian study catchment area was roughly 275 km2,
located at two sites, one to the east and the other to the
west of Farafenni, a rural town 170 km to the east of the
Atlantic coast. During cross-sectional malaria surveys,
between 7% to 9% of children under five years of age were
found to be parasitaemic. The overall the malaria attribut-
able mortality in this region in the 1980s was estimated to
be 6.3 per 1,000 in children under the age of one year and
10.7 per 1000 in children aged 1–4 years [22]. Transmis-Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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sion was highly seasonal following the rains in July to
September with an EIR of approximately 4 [23] with a
peak of clinical attacks at the end of the wet season. Symp-
tomatic malaria was rare between February and July. Data
used in our study comes from three studies [16,24,25].
Thailand
The studies in Thailand were carried out in camps for dis-
placed persons of the Karen ethnic minority on the west-
ern border of Thailand. Transmission of malaria was
unstable and seasonal, occurring through out the year
with peaks in May-July and December-January [26]. The
estimated EIR and corresponding incidence of malaria
was low (approximately 0.5 to 1.5 cases/person/year)
with prevalence rates of 1–4% for P. falciparum [26]. Over-
all, P. falciparum accounted for 37% of malaria infections,
with the remainder due to Plasmodium vivax. All P. falci-
parum infections and approximately 90% of P. vivax infec-
tions were symptomatic, but the case fatality rate was low
(~0.1%). Severe disease was more common in young chil-
dren and pregnant women [27]. Between 1989 and 2000,
more than 10,000 people were enrolled in more than 25
drug studies. The data come from an amalgamation of 18
studies (mostly comparative trials, but some simply mon-
itoring therapy) conducted between 1990 and 1996
[28,29]. Data from the artemether-lumefantrine studies
were gathered between 1996 and 1999 [30,31].
Design of studies
In all studies symptomatic patients attending outpatient
clinics were considered for enrolment. In Thailand,
patients of all ages were enrolled providing that they
weighed more than five kilograms, whereas in Tanzania,
all patients were older than one year (range 1–67 years).
In The Gambia all patients were under ten years of age,
weighed more than five kilograms and had a parasitaemia
greater than 500 per microlitre in the presence of a febrile
illness. Fully informed consent was obtained from all
patients or their parents or guardians. Pregnant women
and patients with severe disease were excluded at all three
sites.
Patients were monitored following drug treatment in
Thailand weekly until day 28 in early studies, and until
day 63 in later studies. In Tanzania post-treatment follow
up was weekly until day 28, while in The Gambia follow
up was on day 7, day 14 and day 28.
Parasite counting
Parasite counts were calculated from Giemsa-stained thick
and thin blood films. In Thailand, parasitaemia was
expressed as the number of parasitized erythrocytes per
1,000 red cells or the number of parasites seen on the
thick film per 500 white blood cells; in The Gambia and
in Tanzania it was expressed per 200 white blood cells.
Gametocyte density was determined on the basis on the
number of gametocytes per 500 white blood cells in Thai-
land and Tanzania, and per 1,000 white cells in The Gam-
bia. In Tanzania slides were declared negative if no
parasite was seen in 100 high power fields.
Description of the data
In all studies patient characteristics were recorded at
enrolment including: age, sex, haematocrit, temperature,
parasitaemia, length of the illness before enrolment, size
of liver, size of spleen and the patient's symptoms. The
size of the liver, spleen, the haematocrit and parasitaemia
were also measured at the follow-up examinations. In
majority of patients in Tanzania parasitaemia was only
recorded as a categorical variable with five levels: < 800/
μL, 800–1,599/μL, 1,600–3,999/μL, 4,000–19,999/μL
and ≥ 20,000/μL. Patients with no recorded parasitaemia
on enrolment were excluded from the analyses.
There was a considerable variability in malaria treatments
between the studies. In Thailand chloroquine and sul-
phadoxine-pyrimethamine were not evaluated because of
the high level resistance. Artemisinin derivatives either
alone or in combination were the only drugs evaluated at
all three locations. Eight treatment groups were defined
(Table 1).
Four principal outcomes were evaluated:
(i) presence of gametocytes on enrolment (binary);
(ii) appearance of gametocytes after enrolment up to day
14 (binary);
(iii) length of gametocyte carriage within 28 days follow-
up (continuous);
(iv) level of maximum gametocytaemia (continuous).
Presence of gametocytes on enrolment was defined as a
gametocytaemia detected by microscopy on day 0. Only
patients with a recorded count available on day 0 were
included in the analysis of this endpoint. Appearance of
gametocytes after enrolment up to day 14 was defined in
patients with no detectable gametocytaemia on enrol-
ment and, for the purpose of comparison between sites,
was assessed only from patients with blood slide assess-
ments on days 7 and 14. For the analysis of factors associ-
ated with gametocytaemia within each site, in addition to
mandatory counts on days 7 and 14, counts between days
1 and 6, if available, were used to evaluate carriage. Thus
for this analysis, if there was a positive count at anytime in
the first two weeks, the patient was classified as gametocy-
taemic regardless of availability of counts on day 7 or 14.Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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The duration of gametocyte carriage was defined as the
time from the first recording of gametocytaemia until half
way between the last positive record and the subsequent
negative record. For patients with missing records after a
positive record of gametocytaemia, half way between the
last positive record and the next scheduled assessment (7,
14, 21 or 28 days) was used to calculate duration of car-
riage, and these observations were treated as censored. For
patients with intermittent gametocytaemia, duration of
carriage was defined as time from the first positive count
to the last positive count recorded. Missing assessments
between positive counts were treated as positive. Maxi-
mum gametocytaemia was defined as the maximum den-
sity of gametocytaemia recorded over the whole follow-up
period.
Infectivity was not assessed in these studies. Whilst accept-
ing that the relationship between infectivity and parasite
densities is dependent on many factors and varies consid-
erably between individuals, there is nevertheless a quanti-
tative relationship between the two. To illustrate this,
gametocytaemia-infectivity relationships from two data
sets were used to construct putative infectivity. For each
patient gametocyte densities on days 0, 7, 14, 28 were
used to interpolate (using the straight line interpolation
between two subsequent points) levels for all days
between day 0 and day 28. These levels were then con-
verted into the probabilities pi  of infecting a feeding
anopheline mosquito on the i-th day using a sigmoid rela-
tionship (Figure 1) obtained from fitting a non-symmetric
Gompertz model to the estimated proportion of infected
mosquitoes:
Method A: 1.08 exp(- exp(-0.86*(log10(gametocyte
count) * – 1.48)))
This is a data set derived from non-immune volunteers
[15].
Method B: 0.07 + 0.38 exp(-exp(-4.09 *(log10(gametocyte
count) – 2.09)))
This is a data set derived from semi-immune children in
The Gambia [16].
The model fits were satisfactory (both R2 ≥ 0.99) with the
estimated values between the observed values close to lin-
Table 1: Malaria treatments evaluated and their estimated efficacy
Treatment Group Failure Rate (95% CI)1 (%)
Number of patients treated
Thailand The Gambia Tanzania
Artemisinin derivatives ± other drugs (A) 15 (14–17)
5324
9 (7–12)
1207
27 (20–36)
130
Antipyretics only (B) 33 (13–70)
32
Chloroquine (C) 42 (31–55)
120
62 (58–66)
1115
Halofantrine (D) 14 (11–18)
459
Mefloquine only (E) 32 (27–37)
1423
Quinine regimens (F) 22 (17–28)
311
75 (31–93)
8
Sulfadoxine-Pyrimethamine (G) 8 (5–11)
693
46 (29–67)
70
Sulfadoxine-Pyrimethamine + Chloroquine (H) 50 (21–87)
13
1 defined as recurrent parasitaemia within 42 days for Artemisinin derivatives (A) and Mefloquine (E) and 28 days for other treatments; estimated 
using Kaplan-Meier method.Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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ear interpolation. The same relationship was used for all
treatments.
As a measure reflecting overall infectivity of an individual,
the area under the curve (AUIC) of the probability of
infecting a biting female anopheline mosquito and time
was estimated [17] and expressed in infectivity days. This
was calculated using trapezoid rule as any short segment
of the infectivity curve could be approximated by a
straight line. This measure reflects the potential gameto-
cyte exposure to feeding anopheline mosquitoes, but does
not take into account any individual drug effect on infec-
tivity which is independent of gametocyte density (such as
sporontocidal activity). As a measure of overall infectivity
of a population the individual AUICs from all patients
(carrying gametocytes or not) were added up and pre-
sented per 1,000 patients.
Statistical analysis
Failure rates were estimated by survival analysis using
Kaplan-Meier method. Recurrence of parasitaemia was
treated as failure and patients lost to follow-up were cen-
sored at the last follow-up visit.
The association between the area under the gametocyte
density time curve (AUC) and gametocyte count on day 7
was examined using Spearman's correlation. AUC was cal-
culated using trapezoid method over 28 day follow-up
period and was restricted to patients who had measure-
ments taken on day 0,7,14 and 28. To calculate AUC and
AUIC, it was assumed that missing counts which follow
gametocytaemia clearance (i.e. at least one negative count
after positive counts) remained negative. To avoid con-
founding with recrudescence or reinfection in assessing
the asexual to sexual stage transition, the ratio between
maximum gametocytaemia and maximum asexual parasi-
taemia was calculated only in patients with maximum
Relationship between infectivity and gametocytaemia level: (A) Jeffery-Eyles (B) Drakeley et al Figure 1
Relationship between infectivity and gametocytaemia level: (A) Jeffery-Eyles (B) Drakeley et al.
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gametocytaemia recorded within 14 days after starting
treatment. Parasitaemia on enrolment was used for the
maximum parasitaemia.
For the purpose of analyses the following variables were
dichotomized: temperature (oral > = 38C or axillary >
37.5C), history of illness (> = 3 days), liver size (> 0 cm),
spleen size (> 0 cm). Anaemia and severe anaemia were
defined on the basis of haematocrit using cutoffs of 30%
and 20% respectively. Parasitaemia on enrolment was
examined as a categorical variable. The effect of continu-
ous parasitaemia (after log 10 transformation) was also
examined in studies with available data.
The duration of gametocyte carriage was analysed by sur-
vival methods. Kaplan-Meier estimates (K-M) of gameto-
cyte carriage rates were calculated at day 7 and 14 and
compared between groups using the log-rank test strati-
fied by study site. Heterogeneity of results between studies
within each country was examined through the test of
interaction in the Cox proportional hazards model. As the
proportional hazards assumption was not satisfied
between sites, effects of covariates in the combined data-
set and their interaction with site were examined in a log-
normal model with accelerated failure-time
parameterization and with gamma frailty (to account for
study and site effects) [32].
Associations between maximum gametocytaemia and
explanatory variables were examined using a negative
binomial regression model [33,34] with random effects to
accommodate study variation in dispersion. Results were
summarized in groups of patients by ratios of mean den-
sities (exponent of the regression coefficients). Only
patients who carried gametocytes at some time during the
follow-up contributed to this analysis.
Relationships between binary outcomes and explanatory
variables were examined using the Mantel-Haenzel
method, stratified by study site. The effects of covariates
and their interaction with country in the combined data
set were explored using logistic regression models with
random effects. In all analyses, unless stated otherwise,
age, haematocrit and enrolment parasitaemia were treated
as continuous covariates. Enrolment parasitaemia was
log-transformed and haematocrit was adjusted for each
site population median.
In multivariate analyses, all covariates examined in corre-
sponding univariate analyses were investigated. Final
models were selected by stepwise forward variable selec-
tion procedure and only covariates significant at 5% were
included in the final model. For continuous variables cat-
egorical and continuous representations were investigated
and the one which maximized the log-likelihood function
was selected. If the difference in the log-likelihood was
not significant, the continuous representation was
selected.
All analyses were performed on the maximum possible
data set, i.e. on all patients with non-missing required
data and since different analysis used different endpoints
and covariates different subsets of patients were analysed
throughout the paper. Numbers of patients used in each
analysis are given.
Results
In total, there were 10,968 patients with confirmed falci-
parum malaria on enrolment and at least one gametocyte
assessment available on enrolment or during the follow-
up. Treatments administered and their efficacies are sum-
marized in Table 1.
The demographic characteristics of patients in the three
populations studied are shown in Table 2. There was a sig-
nificant difference in the age distribution between sites.
After adjustment for age the patients in Thailand were less
anaemic (p < 0.001) and had lower parasite counts (p <
0.001) than in the two African study sites. Figure 2 shows
the distributions of enrolment parasitaemia, age and hae-
matocrit for the three sites.
General description
Overall, 19% (2044/10,968) of patients had patent game-
tocytaemia during the observation period: 12% (931/
7548) in Thailand, 34% (683/2020) in The Gambia and
31% (430/11400) in Tanzania (p < 0.001, chi-square
test). Approximately one third (33%, 680/2044) of the
patients with gametocytaemia at some stage of the infec-
tion, already had patent gametocytaemia at enrolment
(day 0 or day 1): 35% (318/931) in Thailand, 37% (250/
683) in The Gambia, 26% (112/430) in Tanzania. Maxi-
mum gametocyte densities were different between the
sites, being lowest in Tanzania (median = 55/μL), highest
in The Gambia (median = 256/μL) and with a median
maximum gametocytaemia of 180/μL in Thailand (p <
0.001, Kruskal-Wallis test). In patients presenting with
gametocytes the maximum recorded gametocytaemia
occurred on or before day 7 in 99% of Thai patients, 90%
of those in Tanzania and 95% in patients from The Gam-
bia. In patients who developed gametocytaemia after
enrolment, the maximum gametocytaemia was usually
recorded on day 7 but in 30% patients in Gambia, 40% in
Tanzania, and 11% in Thailand it occurred after day 7 of
follow-up. The area under the gametocyte count-time
curve was correlated with gametocytaemia level on day 7;
Spearman correlation coefficient of 0.86 (The Gambia; n
= 416), 0.57 (Tanzania, n = 198) and 0.42 (Thailand; n =
729) (all p < 0.001). The median (IQR) number of meas-Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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urements per patients was 4 (4–4), 5(4–5) and 8 (7–11),
respectively.
The ratio between maximum gametocytaemia and maxi-
mum asexual parasitaemia (a measure of the asexual to
sexual stage transition rate) was the lowest (median, 90%
range) in Tanzania 0.0008 (0.0001–0.04) n = 16, com-
pared with The Gambia 0.01 (0.0002–1.10) n = 614, and
Thailand 0.04 (0.0005–1.77) n = 725 (p < 0.001, Kruskal-
Wallis test). The ratio was significantly lower (p < 0.001)
in the youngest age group in The Gambia and there was
no difference between age groups in Thailand. The ratio
was also significantly lower in patients who developed
gametocytes after enrolment (median [90% range] = 0.01
[0.0002–0.80]) as compared to those with gametocytes at
enrolment (0.05 [0.001–2.67]); p < 0.001. In patients
who had any parasitaemia assessments between day 0 and
day 7, 79% had maximum parasitaemia recorded on day
0. In the others, the ratio between maximum parasitaemia
and enrolment parasitaemia was median (90% range) =
2.6 (1–50).
Gametocytaemia on enrolment
Overall, 12% (250/2018) of The Gambian patients had
gametocytaemia recorded on enrolment compared to 8%
(112/1400) in Tanzania and 4% (318/7502) in Thailand
(Table 3); p < 0.001.
Risk factors for admission gametocyte carriage included:
lower parasitaemia and anaemia in all sites; younger age
in Thailand and Tanzania; lower body temperature in
Thailand and The Gambia; and longer history of illness,
palpable liver, palpable spleen, and pure P. falciparum
infection in Thailand (Table 3).
Figures 3, 4, 5 show the distributions of enrolment parasi-
taemia, haematocrit and temperature for patients with
and without gametocytes at enrolment, by site.
A multivariate analysis could be conducted in three sites
separately (Table 4) and for combined data from Thailand
and The Gambia only because of different characteristics
being collected in Tanzania. For The Gambia, Thailand
Table 2: Demographic characteristics of patients in the three populations
Thailand The Gambia Tanzania
Total number of patients 7548 2020 1400
Age (years)1 13 (2–43) 4 (1–10) 4 (1–32)
Male2 3183 (56%) 613 (54%) 487 (43%)
History of illness (days)1 2 (0–5) No Data 3 (0–7)
Symptoms present2 5458 (97%) No Data 922 (88%)
Haematocrit (%)1 35 (25–44) 30 (20–39) 31 (18–40)4
Palpable liver2 868 (16%) 221 (20%) No Data
Palpable spleen2 1197 (22%) 517 (45%) No Data
Axillary temperature1 37.7 (36.1–39.6) 37.8 (36.2–40) No Data
Parasitaemia (/μL)1 6,920 (166–183,920) 32,500 (1,360–311,575) 59,400 (7,992–271,913)5
Parasitaemia (/μL)2,3
≤ 1,600 1,867 (25%) 117 (6%) 395 (28%)
1,600–4,000 1,100 (15%) 142 (7%) 454 (32%)
4,000–20,000 2,206 (29%) 499 (25%) 262 (19%)
> 20,000 2,330 (31%) 1,262 (62%) 289 (21%)
1 median and 90% range are presented.
2 number (%) of patients with this characteristic.
3 n = 49 patients in Thailand had confirmed parasitaemia on admission but the actual count was not recorded.
4 data available for n = 65.
5 data available for n = 257.Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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and their combined data, only enrolment parasitaemia,
haematocrit and temperature were selected in the final
model. In the combined model, after adjusting for these
covariates, gametocyte carriage rates were still much lower
in Thailand (OR [95%CI] = 0.048 [0.029–0.075], p <
0.001) then in The Gambia. Although duration of illness
and presence of mixed infection was a risk factor in Thai-
land they could not be tested in the overall model as they
were not recorded in The Gambia. The odds ratios con-
firm the univariate results, and for parasitaemia (OR
[95%CI] = 0.580 [0.492–0.683], p < 0.001) and tempera-
ture (OR [95%CI] = 0.593 [0.452–0.779], p < 0.001) were
similar for the two sites, whereas there were significantly
different values for enrolment haematocrit (OR [95%CI]
= 0.902 [0.876–0.930] in The Gambia and 0.834 [0.805–
0.864] in Thailand, p < 0.001, likelihood ratio test). In
Tanzania only age and parasitaemia were selected in the
final model.
Gametocytaemia after enrolment
In those patients who presented without gametocytes on
enrolment, only 3% (122/4,083) overall developed game-
tocytes carriage during follow up after treatment with
artemisinin derivatives. This proportion varies across
sites. It was highest in The Gambia; 15% (96/645) com-
pared with 0% (0/100) and 1% (26/3338) in Tanzania
and Thailand. However, it should be noted that 10
patients in Tanzania and 109 in Thailand had gametocy-
taemia recorded between days 1 and 6 but as their read-
ings were negative on day 7 and 14, they were included in
these comparisons as not gametocytaemic. Sulphadoxine-
pyrimethamine (SP) was associated with the greatest car-
riage rates (64% 221/348) and this effect was similar in
Distribution of admission characteristics of patients in the three countries: (A) parasitaemia, (B) age, (C) haematocrit Figure 2
Distribution of admission characteristics of patients in the three countries: (A) parasitaemia, (B) age, (C) hae-
matocrit.
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Table 3: Univariate analysis of gametocytaemia at enrolment
% (N) with gametocytes at enrolment
OR [95% CI]
P-value
All
(N = 10,920)
Thailand
(N = 7,502)
The Gambia
(N = 2,018)
Tanzania
(N = 1400)
Total1 6 (680)
< 0.0011
4 (318) 12 (250) 8 (112)
Age (years)2
0–5 8 (270) 2 (31) 13 (151) 11 (88)
5–15 5 (203) 3(90) 13 (99) 5 (14)
> 15 6 (207) 6 (197) 0 (0) 4 (10)
0.980 [0.971–0.988] 0.986 [0.975–0.997] 0.962 [0.917–1.009] 0.966 [0.950–0.983]
< 0.001 < 0.013 0.114 < 0.001
Symptoms
Yes 3 (195) 2 (103) No Data 10 (92)
No 5 (17) 4 (7) 8 (10)
0.962 [0.576–1.608] 0.510 [0.228–1.142] 1.330 [0.673–2.627]
0.883 0.095 0.410
History of illness
= 3 days 6 (64) 4 (28) No Data 11 (36)
< 3 days 3 (147) 2 (79) 8 (68)
1.659 [1.214–2.267] 1.978 [1.250–3.130] 1.445 [0.943–2.216]
0.001 0.003 0.089
Sex
Male 5 (223) 2 (59) 19 (114) 10 (50)
Female 5 (190) 2 (51) 16 (85) 8 (54)
1.129 [0.918–1.389] 0.912 [0.623–1.336] 1.213 [0.888–1.657] 1.271 [0.848–1.905]
0.250 0.637 0.225 0.244
Severe Anaemia
Yes 33 (36) 17 (7) 43 (27) 40 (2)
No 5 (304) 2 (83) 13 (200) 34 (21)
4.475 [2.856–7.011]4 10.331 [4.459–23.462]4 4.322 [2.494–7.491] 1.238 [0.189–8.126]
< 0.001 < 0.001 < 0.001 0.834
Anaemia
Yes 14 (204) 6 (47) 21 (144) 50 (13)
No 3 (136) 1 (43) 9 (83) 26 (10)
2.921 [2.305–3.703]4  4.346 [2.902–6.510]4 2.477 [1.830–3. 354] 2.900 [0.970–8.671]
< 0.001 < 0.001 < 0.001 0.050
Haematocrit2 0.877 [0.860–0.895]4 0.819 [0.789–0.850]4 0.897 [0.874–0.920] 0.942 [0.882–1.007]
< 0.001 < 0.001 < 0.001 0.080
Palpable liver
Yes 7 (72) 3 (28) 20 (44) No Data
No 4 (227) 2 (75) 17 (152)
1.613 [1.178–2.209] 1.978 [1.269–3.084] 1.355 [0.868–2.116]
0.003 0.002 0.179
Palpable spleen
Yes 8 (137) 3 (38) 19 (99) No Data
No 3 (164) 2 (64) 16 (100)
1.552 [1.296–1.998]4 2.183 [1.464–3.254]4 1.288 [0.928–1.786]
< 0.001 < 0.001 0.129Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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Tanzania and The Gambia (p = 0.215, chi square test). The
corresponding overall rates for developing patent gameto-
cytaemia on day 7 or day 14 after the other treatments
were 29% (114/390) following chloroquine, 3% (10/
349) following halofantrine, 6% (53/878) after meflo-
quine, and 22% (34/153) after quinine.
In the univariate analyses (Table 5), statistically signifi-
cant associations were also found between the develop-
ment of gametocytaemia and young age, long history of
illness, anaemia and high parasitaemia on enrolment. In
Thailand also palpable spleen, palpable liver and pure P.
falciparum infection were associated with increased risk of
gametocytaemia. In the multivariate analyses (Table 6), in
Thailand and The Gambia, low haematocrit on enrolment
(OR [95%CI] = 0.875 [0.852–0.898] in Thailand and
0.965 [0.938–0.994] in The Gambia) was associated with
an increased risk of the appearance of gametocytaemia. In
addition, Thai patients with a palpable spleen (OR
[95%CI] = 1.433 [1.050–1.955]) and long history of ill-
Axillary Temperature
> = 37.5C 3 (133) 1 (41) 13 (92) No Data
< 37.5C 7 (176) 3 (68) 24 (107)
0.494 [0.404–0.604] 0.660 [0.554–0.786] 0.502 [0.367–0.687]
< 0.001 < 0.001 < 0.001
Mixed infection on admission
Yes - 1 (6) No Data No Data
No 5 (312)
0.354 [0.152–0.821]
0.011
Parasitaemia2,3(/μL)
≤ 1,600 7 (170) 5 (88) 22(26) 14(56)
1,600–4,000 6 (101) 5 (54) 14(20) 6 (27)
4,000–20,000 8 (224) 5 (195) 20(100) 7 (19)
> 20,000 5 (185) 3 (71) 8(104) 3 (10)
0.688 [0.632–0.749]4 0.517 [0.443–0.604] 0.600 [0.495–0.728] 0.681 [0.543–0.853]
< 0.001 < 0.001 < 0.001 0.001
1 p-value from chi-square test
2 OR and test for the continuous representation;
3 The Gambia, Thailand: OR calculated for log10 parasitaemia; Tanzania, All : OR for ordered categories, p-value is for test for trend.
4 p-value for homogeneity < 0.05
Table 3: Univariate analysis of gametocytaemia at enrolment (Continued)
Box plots of admission parasitaemia for patients in the three countries with/without gametocytes present Figure 3
Box plots of admission parasitaemia for patients in the three countries with/without gametocytes present.
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ness (OR [95%CI] = 2.909 [2.126–3.981]) and pure P.fal-
ciparum infection (OR [95%CI] = 2.762 [1.559–4.901])
and Gambian patients with high parasitaemia on enrol-
ment (OR [95%CI] = 1.503 [1.177–1.919]) were at
increased risk of developing gametocytaemia In all coun-
tries, treatment with artemisinin derivatives alone or com-
bined with other drugs resulted in the lowest risk of
gametocytaemia. In Tanzania, apart from the treatment,
only young age was associated with gametocyte carriage
after enrolment. Different sampling schedules prohibited
us from combining data from different sites.
Length of gametocyte carriage
Of the 2027 patients with gametocytes before day 28, 12
(0.6%) had three and 164 (8%) had two separated epi-
sodes of gametocytes carriage, with a negative count
between positive counts. Among a total of 2213 episodes,
only 58 (3%) had one missing measurement and 7
(0.3%) episodes had 2 or more missing measurements
between the first and last counts. Quality of the follow-up
information varied between sites, with 68% censored
observations in The Gambia, 61% in Tanzania and 19%
in Thailand, although one third of these in The Gambia
and one quarter in Tanzania were censored after day 14.
Box plots of admission body temperature for patients in the three countries with/without gametocytes present Figure 4
Box plots of admission body temperature for patients in the three countries with/without gametocytes 
present.
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Box plots of admission haematocrit for patients in the three countries with/without gametocytes present Figure 5
Box plots of admission haematocrit for patients in the three countries with/without gametocytes present.
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The proportion of patients who had missing measure-
ments before the first positive gametocyte count was 7%,
6% and 2% in Tanzania, The Gambia and Thailand.
Gametocyte carriage rates (95% CI) after 7 and 14 days
were smallest in Thailand (Table 7): 34(31–37)% and
19(16–22)%. In The Gambia and Tanzania rates were
very similar (p = 0.99, logrank test) and at least twice the
rates in Thailand. In each site, gametocyte carriage rates
after 7 days in patients who were treated with artemisinin
derivatives alone or with other drugs were significantly
lower than rates of carriage in patients on other treat-
ments: 33(30 – 36)% versus 62% (58–65)% for patients
treated with monotherapies (groups C-F) and 85 (71–
88)% for patients treated with sulphadoxine-pyrimeth-
amine (groups G-H) in all sites combined (p < 0.001,
logrank test stratified by study). The corresponding game-
tocyte carriage rates (95%CI) after 14 days were 18 (15–
21)%, 47 (43–51)% and 80 (75–84)%.
In Thailand other risk factors for prolonged carriage
included high enrolment parasitaemia (p = 0.005), a pro-
longed history of illness (p = 0.038) and anaemia (p =
0.034). These associations were not apparent in the other
sites.
Site, presence of gametocytaemia on enrolment, haemat-
ocrit and treatment were all independent predictors of the
duration of gametocyte carriage in the multivariate analy-
sis of the combined data from Thailand and The Gambia
(Table 8). In Thailand carriage was 86% shorter than in
The Gambia. In patients who received artemisinin deriva-
tives carriage was shortened in duration by 27% in Thai-
land and by 71% in the Gambia. In The Gambia,
gametocytaemia present before treatment had a 72%
Table 4: Multivariate analysis – gametocytaemia at enrolment.
OR [95% CI]
P-value
Thailand
(N = 4432)
The Gambia1
(N = 1091)
Tanzania1
(N = 1383)
Log10 Parasitaemia 0.448 [0.373–0.612] 0.688 [0.549–0.862] No Data
< 0.001 0.001
Parasitaemia (/μL) NS NS
< 1,600 1.000
1,600–4,000 0.266 [0.161–0.440]
< 0.001
4,000–20,000 0.293 [0.164–0.524]
< 0.001
≥ 20,000 0.175 [0.067–0.455]
< 0.001
Haematocrit 0.830 [0.8001–0.861] 0.900 [0.873–0.927] No Data
< 0.001 < 0.001
No Data
Axillary Temperature
< 37.5 1.000 1.000
> = 37.5 0.550 [0.348–0.867] 0.629 [0.447–0.886]
< 0.001 0.008
Age (years) NS NS
0–5 1.000
5–15 0.244 [0.133–0.447]
< 0.001
> 15 0.155 [0.077–0.311]
< 0.001
Only covariates significant in at least one model are shown.
1 fixed effects model was fitted since test for random effects not significant.
NS – not significant in the multivariate model.
No Data – no data was collected at the siteMalaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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Table 5: Univariate analysis-presence of gametocytes after enrolment up to day 14
% (N) with gametocytes
OR [95%]
P-value
All
(N = 6793)
Thailand
(N = 5069)
The Gambia
(N = 1110)
Tanzania
(N = 614)
Total1 15 (998) 7 (342) 36 (400) 42 (256)
< 0.0012
Age (years)3
0–5 28 (530) 13 (118) 40 (249) 41(163)
5–15 16 (432) 10 (202) 33 (159) 56 (62)
> 15 13 (293) 12 (251) 75 (3) 40 (39)
0.985 [0.979–0.992] 0.987 [0.979–0.995] 0.963 [0.918–1.011] 0.978 [0.963–0.993]
< 0.001 0.001 0.131 0.005
Symptoms
Yes 14 (546) 10 (364) No Data 51 (182)
No 25 (42) 9 (10) 57 (32)
0.936 [0.586–1.486] 1.147 [0.580–2.268] 0.0.784 [0.444–1.387]
0.784 0.694 0.403
History of illness
> = 3 days 30 (193) 25 (129) No Data 48 (64)
< 3 days 12 (408) 8 (234) 57 (174)
2.030 [1.658–2.484]5 3.400 [2.640–4.380] 0.683 [0.453–1.029]
< 0.001 < 0.001 0.067
Sex
Male 18 (446) 10 (203) 39 (136) 57 (107)
Female 19 (421) 10 (172) 37 (117) 52 (132)
1.071 [0.910–1.261] 1.041 [0.836–1.295] 1.052 [0.766–1.445] 1.201 [0.821–1.758]
0.406 0.722 0.754 0.345
Severe Anaemia
Yes 33 (18) 29 (7) 37 (11) No Data
No 17 (636) 10 (287) 34 (341)
1.536 [0.858–2.747]5 2.433 [0.989–5.986]5 1.302 [0.586–2.893]
0.145 0.045 0.515
Anaemia
Yes 32 (294) 26 (136) 38 (157) No Data
No 12 (360) 7 (158) 32 (195)
2.308 [1.920–2.775]5 4.135 [3.156–5.418] 1.402 [1.069–1.840]
< 0.001 < 0.001 0.014
Haematocrit3 0.917 [0.903–0.932]5 0.872 [0.853–0.891] 0.974 [0.950–0.998] No Data
< 0.001 < 0.001 0.037
Palpable liver
Yes 21 (156) 17 (100) 40 (56) No Data
No 13 (449) 9 (256) 37 (193)
1.725 [1.378–2.162] 1.965 [1.513–2.551] 1.216 [0.772–1.918]
< 0.001 < 0.001 0.398
Palpable spleen
Yes 22 (253) 17 (143) 40 (110) No Data
No 11 (355) 8 (212) 36 (143)
1.708 [1.412–2.065]5 2.227 [1.756–2.826]5 1.067 [0.768–1.483]
< 0.001 < 0.001 0.698Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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longer clearance time than gametocytaemia which
appeared after treatment. In Thailand the difference in
clearance time was not significant. Carriage was longer in
people presenting with anaemia by 27% in both coun-
tries.
When a common model was fitted for all three data sets
using common covariates (anaemia could not be included
since it was missing for majority of patients in Tanzania),
gametocyte carriage in Tanzania was estimated to be
shorter by 65% than gametocyte carriage in The Gambia.
Effects of gametocytaemia on admission and treatment
with artemisinin derivatives in Tanzania were estimated
to be the same as in The Gambia.
Maximum gametocytaemia
In Thailand, the maximum gametocyte density was
increased in patients with gametocytaemia on enrolment
(Incidence Rate Ratio (IRR) [95%CI] = 1.261 [1.081–
1.430], p = 0.001, n = 925), severe anaemia (IRR [95%CI]
= 1.744 [1.136–2.677], p = 0.011, n = 403) and a pro-
longed history of illness (> 3 days) (IRR [95%CI] = 1.234
[1.047–1.455], p = 0.019, n = 491). The two children age
groups (< 5 years and 5–15 years) had similar levels of
maximum gametocytaemia which were significantly
higher than in adults (IRR [95%CI] = 1.135 [1.002–
1.284], p = 0.046, n = 931). The effects of these covariates
were the same for patients presenting with gametocytae-
mia on enrolment and patients who developed gametocy-
taemia later, as tested by the interaction term in the
model. No covariates were significant in the multivariate
analysis.
In The Gambia, the only determinant of maximum game-
tocyte density was drug treatment, but this effect was dif-
ferent for patients presenting with gametocytaemia on
enrolment and patients who developed gametocytaemia
later (p = 0.009, n = 651). In both cases, patients treated
with SP produced higher number of gametocytes than
patients treated with artemisinin derivatives (IRR [95%CI]
Temperature
> = 37 C 14 (385) 9 (213) 40 (172) No Data
< 37.5 C 15 (242) 11 (161) 33 (81)
0.947 [0.785–1.141] 0.831 [0.664–1.040] 1.273 [0.904–1.794]
0.564 0.106 0.165
Parasitaemia3,4(/μL)
≤ 1,600 13 (187) 9(110) 25 (16) 46 (61)
1,600–4,000 20 (205) 10(76) 30 (28) 57 (101)
4,000 – 20,000 18 (355) 12(185) 34 (100) 55 (70)
> 20,000 21 (502) 13 (200) 41 (267) 20 (35)
1.120 [1.013–1.238] 1.053 [0.936–1.184] 1.335 [1.907–1.625] 1.182 [0.960–1.458]
0.027 0.394 0.004 0.115
Mixed infection
Yes 4 (22)
No No Data 12 (549) No Data No Data
0.366 [0.236–0.567]5
< 0.001
Treatment6
A 10 (413) 8 (287) 16 (106) 10 (11)
C-F 26 (516) 18 (276) 27 (13) 49 (227)
3.073 [2.384–3.962] 3.063 [2.330–4.026] 3.259 [1.028–10.387] 4.751 [1.530–14.754]
< 0.001 < 0.001 0.033 0.003
G-H 70 (301) No Data 71 (283) 62 (18)7
11.744 [8.019–17.199] 11.936 [8.136–17.510]
< 0.001 < 0.001
1 Percentages are calculated from patients with both non-missing counts on day 7 and day 14 (out of 4840, 1099 and 603 patients, respectively)
2 p-value from chi-square test
3 OR and test for the continuous representation
4 The Gambia, Thailand: OR calculated for log10 parasitaemia; Tanzania, All : OR for ordered categories, p-value is for test for trend.
5 p-value for homogeneity < 0.05
6 treatments groups are defined as: A: artemisisnin combination alone or with other treatments; C-F: other monotherapies (see Table 1); G-H: SP 
alone or SP with chloroquine. OR are calculated with reference to group A.
7 G-H/A at separate sites
Table 5: Univariate analysis-presence of gametocytes after enrolment up to day 14 (Continued)Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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= 1.880 [1.533–2.306] for patients presenting without
gametocytaemia, 1.404 [1.106–1.7] for patients present-
ing with gametocytaemia).
In Tanzania, higher gametocyte densities were found in
patients with high parasitaemia on enrolment (IRR
[95%CI] = 1.461 [1.301–1.640] for increase in parasitae-
mia up to the next category, p < 0.001 test for trend, n =
430), females (IRR [95%CI] = 1.595 [1.244–2.045], p <
0.001, n = 391), anaemic patients (IRR [95%CI] = 2.427
[1.128–5.222], p = 0.012, n = 33), and symptomatic
patients (IRR [95%CI] = 1.730 [1.186–2.524], p = 0.004,
n = 362). Children aged 5–15 years (IRR [95%CI] = 0.584
[0.431–0.790], p < 0.001) and adults (IRR [95%CI] =
0.253 [0.176–0.363], p < 0.001) had significantly lower
gametocyte densities compared to children less than 5
years of age (n = 427). In the multivariate model only age
(IRR [95%CI] = 0.583 [0.439–0.795] for 5–15 years,
0.317 [0.207–0.424] for > 15 years, as compared to chil-
dren 0–5 years) and parasitaemia (IRR [95%CI] = 2.201
[1.542–3.142] for parasitaemia increase up to the next
category, p < 0.001, test for trend) remained independent
determinants of gametocyte density. Anaemia was not
investigated in the multivariate analysis due to the large
number of missing values. Since multivariate analyses in
each site resulted in models with no common covariates
no analysis was performed on the combined data set.
Table 6: Multivariate analysis for gametocytaemia after enrolment up to day 14.
OR [95% CI]
P-value
Thailand
(N = 2633)
The Gambia
(N = 1031)1
Tanzania
(N = 592)
Log 10 parasitaemia NS 1.503 [1.177–1.919]
0.001
No Data
History of illness No Data NS
< 3 days 1.000
> = 3 days 2.909 [2.126–3.981]
< 0.001
Haematocrit 0.875 [0.852–0.898] 0.965 [0.938–0.994] No Data
< 0.001 0.017
Palpable spleen No Data NS
No 1.000
Yes 1.433 [1.050–1.955]
0.023
Mixed infection 0.362 [0.204–0.641] No Data No Data
0.001
Treatment2
A 1.000 1.000 1.000
C-F 2.964 [2.048 4.290] 1.661 [0.709–3.893] 3.432 [1.483–7.946]
< 0.001 0.243 0.004
G-H 12.320 [8.757–17.333] 5.520 [1.724–17.675]
< 0.001 0.002
Age (years) NS NS
0–5 1.000
5–15 0.750 [0.465–1.210]
0.238
> 15 0.409 [0.250–0.671]
< 0.001
Only covariates significant in at least one model are shown.
1 fixed effects model was fitted since test for random effects not significant
2 treatments groups are defined as: A: artemisisnin combination alone or with other treatments;
C-F: other monotherapies (see Table 1); G-H: SP alone or SP with chloroquine. OR are calculated with reference to group A.Malaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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Table 7: Estimated gametocyte carriage rates (GCR)
All
(N = 2027)
Thailand
(N = 922)
The Gambia
(N = 681)
Tanzania
(N = 424)
GCR (%) after 7 days (95% CI)
Overall 54 (52–56) 34 (31–37) 65 (61–69) 71 (66 – 75)
Gametocytaemia on enrolment
No 53 (50–55) 32(28–36) 71 (66–75) 69 (64–75)
Yes 58 (39–45) 40 (35–45) 77 (71–82) 75 (66–82)
Treatment
A 33 (30–36) 24(20–28) 54 (48–60) 26 (5–53)
C-F 62 (58–65) 50 (44–55) 81 (63–91) 73 (68–78)
G-H 85 (71–88) 86 (82–89) 66 (45–80)
GCR (%) after 14 days (95% CI)
Overall 41 (38–43) 19 (16–22) 65 (61–69) 57 (51–63)
Gametocytaemia on enrolment
No 42 (39–45) 18 (14–21) 71(66–75) 53(46–60)
Yes 41(37–45) 23 (18–28) 58 (51–64) 65 (54–74)
Treatment1
A 18(15–21) 9 (7–12) 38 (32–45) 13(1–42)
C-F 47(43–51) 34 (29–40) 81 (63–91) 60 (54–66)
G-H 80 (75–84) 83 (77–87) 38 (18–58)
1 treatments groups are defined as: A: artemisisnin combination alone or with other treatments;
C-F: other monotherapies (see Table 1); G-H: SP alone or SP with chloroquine.
Table 8: Parameter estimates from the exponential model with gamma frailty for the length of gametocytes carriage, data from 
Thailand and The Gambia combined, N = 971
Exp(Coefficient)1 95% CI P-value
Study Site
Thailand 0.139 0.099–0.193 < 0.001
The Gambia 1.000
Anaemia 1.266 1.071–1.496 0.006
Treatment with artemisinin derivatives
Thailand 0.725 0.549–0.958 0.024
The Gambia 0.293 0.226–0.380 < 0.001
Presence of gametocytes before treatment
Thailand 0.934 0.704–1.239 0.636
The Gambia 1.723 1.335–2.222 < 0.001
1 Represents change in length of gametocytes carriage relative to the rest of the populationMalaria Journal 2008, 7:249 http://www.malariajournal.com/content/7/1/249
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Predictors of potential infectivity
The putative patient infectivity was estimated from the
serial gametocyte counts. Among patients with gameto-
cytes measurements available on days 0, 7, 14 and 28, all
four blood film examinations were negative for gameto-
cytes in 92% (3,643/3,970) of Thai patients, compared to
63% (177/281) of Tanzanian patients and 54% (373/
685) of patients from the Gambia; p < 0.001. These
patients were excluded from the analysis of infectivity. In
nearly all cases (1012/1017) the area under the infectivity
curve (AUIC) calculated using Method A [15] was median
(range) 102 (4 – 505)% higher than that calculated using
Method B [16]. Among those who carried gametocytes at
some stage of the infection, the area under the infectivity
curve (median [90% range]) was highest in The Gambia
(Method A: 11.2 [2.0–24.2] infectivity days and Method
B: 4.4 [1.9–12.04] infectivity days, n = 426), markedly
lower in Thailand (Method A: 6.3 [2.6–18.3] and Method
B: 2.9 [1.9–11.6] infectivity days, n = 421) and lowest in
Tanzania (Method A: 5.6 [2.3–14.3] and Method B: 1.9
[1.9–5.6] infectivity days, n = 170) (Figure 6). Figures 7
and 8 show distribution of AUIC by treatment group in
Thailand and The Gambia. In Tanzania majority of
patients (78%) received the same treatment. Assuming
that Method A is more appropriate for non-immune
patients in Thailand while Method B is more appropriate
for patients in The Gambia and Tanzania and that 8% of
symptomatic patients in Thailand, 37% in Tanzania and
46% in The Gambia will carry gametocytes at some stage
of the infection; the estimated overall infectivity of a pop-
ulation of 1000 patients during the 28 days follow-up are
609 person infectivity days in Thailand, 901 in Tanzania
Distribution of AUIC for patients in the three countries Figure 6
Distribution of AUIC for patients in the three countries. Only patients with gametocytes are presented: in The Gambia 
426 out of 779 (53%), in Tanzania 170 out of 347 (50%) and in Thailand 421 out of 4064 (10%). Patients who had any missing 
gametocytes measurements on day 0, 7, 14, 28 were not included unless the missing values occurred after the day of gameto-
cyte clearance.
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and 2688 in The Gambia. Assuming that everybody in this
population received one treatment, then these estimates
become 486 person infectivity days for artemisinin deriv-
atives, 530 for halofantrine and 771 for mefloquine in
Thailand; 1812 person infectivity days for SP+AS and
3474 for SP alone in The Gambia; 892 person infectivity
days for chloroquine in Tanzania. The proportion of
patients presenting with gametocytes at enrolment was
the same for the two treatments in Thailand (5%) and The
Gambia (12%).
Discussion
This comparison between three malariaous regions with
very different epidemiological characteristics detected
considerable heterogeneity in P. falciparum gametocyte
carriage. Some of this heterogeneity is explained by
known factors such as the differences in age (a proxy for
cumulative exposure and thus immunity), levels of anae-
mia, and type of anti-malarial drug used [14]. On enrol-
ment, before drug treatment, gametocyte carriage in
Thailand was 4%. This was three-fold lower than in The
Gambia, and two-fold lower than in Tanzania. Within 14
days from starting treatment a further 40% of patients
developed gametocytes in The Gambia and Tanzania,
while only 7% more patients developed gametocytaemia
in Thailand. Duration of carriage was also significantly
longer in the African countries than in Thailand. In con-
trast, gametocytes densities were lowest in Tanzania. All
this is reflected in the AUIC estimates with The Gambia
having the largest individual estimates and Tanzania the
smallest. Nevertheless, after adjusting for the number of
gametocytes carriers, even if different relationships appro-
Distribution of AUIC for patients in The Gambia for different treatment groups Figure 7
Distribution of AUIC for patients in The Gambia for different treatment groups. Only patients with gametocytes 
are presented: in Artesunate +SP group 197 out of 474 (42%), in SP group 214 out of 289 (74%) and in Chloroquine group 15 
out of 36 (42%) patients. Patients who had any missing gametocytes measurements on day 0, 7, 14, 28 were not included unless 
the missing values occurred after the day of gametocyte clearance.
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priate to the immunity status in the three regions were
applied (i.e. Method A in Thailand and Method B in The
Gambia and Tanzania), the Thai population of sympto-
matic patients was still the least infectious, with Tanza-
nian patients being 50% more infectious and patients in
The Gambia being nearly four times as infectious.
Admission gametocytaemia was associated independently
with lower haematocrit, lower parasitaemia, and lower
temperature. Slowing the expansion of asexual parasitae-
mia may have less effect on the persistence of gametocy-
taemia, as gametocytes have greater longevity than the
asexual stages. In Thailand, where duration of illness was
recorded, gametocyte prevalence was associated with a
longer period of illness before presentation. In low trans-
mission settings the majority of gametocytaemic individ-
uals will be symptomatic and seek treatment during the
acute phase of the illness, and the majority of gametocyte
carriage will occur after starting treatment. In the high
transmission settings contribution of asymptomatic carri-
ers is significant and it has been demonstrated that carriers
with submicroscopic densities of gametocytes are capable
of infecting mosquitoes [1,9]. The dynamics of infection
in a high transmission setting where multiple infections
coexist within the human host may also be more condu-
cive to the production of gametocytes [35]. Whichever the
explanation effective anti-malarial treatment will have a
much greater impact on overall malaria transmission in
areas of low transmission intensity than in high transmis-
sion areas, where a smaller fraction of parasitaemic indi-
viduals seeks treatment.
Distribution of AUIC in patients with gametocytes in Thailand in different treatment groups Figure 8
Distribution of AUIC in patients with gametocytes in Thailand in different treatment groups. Only patients with 
gametocytes are presented: 253 patients out of 2864 (9%) in the Artemisinin +Other group, 16 out of 298 (5%) in the Halofan-
trine group and 113 out of 775 (15%) patients in the Mefloquine group. Patients who had any missing gametocytes measure-
ments on day 0, 7, 14, 28 were not included unless the missing values occurred after the day of gametocyte clearance.
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However, transmission intensity often varies greatly over
small geographic distances, and low transmission settings
often contain microfoci of much higher transmission
intensity. For example even in Thailand, there is evidence
of an untreated reservoir of infectious individuals in some
areas [36], although these are now few. Given marked het-
erogeneity in gametocyte dynamics among sites, it is
remarkable that several parameters were consistently asso-
ciated with gametocyte carriage in all three sites; all of
which are indicative of a longer period of infection, which
could reflect an effective host response and the develop-
ment of premunition, poor access to effective treatment in
impoverished rural areas, exacerbated by drug resistance
or a combination of these [37]. Further, the substantial
impact of ACT in reducing post-treatment gametocyte car-
riage was seen across all studies in all three countries [14].
In nearly all patients with gametocytaemia, densities
peaked in the first week after starting treatment (day 0–7).
The day 7 gametocyte density proved a good surrogate for
the area under the gametocytaemia-time curve. The factors
associated with post-treatment gametocytaemia were sim-
ilar to those associated with enrolment gametocytaemia.
There were large differences between treatment regimens;
those containing an artemisinin derivative were associ-
ated with lower and shorter carriage, and treatment with
SP being associated with higher carriage rates and longer
duration. Although there is a relationship between the
administration of anti-malarial drugs and gametocyte
density, these data cannot be translated directly into trans-
mission potential because of the different effects of the
drugs on gametocyte viability [1,16,38-40].
As drug resistant parasites become more prevalent, the
duration of malaria infections lengthens and the propor-
tion of recrudescent infections increases. Recrudescent
infections are cumulatively of longer duration than pri-
mary infections, and are associated with higher rates of
anaemia and gametocyte carriage [34]. Drug resistant par-
asites have been associated with higher gametocyte car-
riage and enhanced mosquito infectivity in the absence of
appreciable clinical or parasitological treatment failure
[41-43]. Therefore, in high transmission areas, where the
impact of treatment on overall malaria transmission is
likely to be less than in areas of low endemicity, ACT can
provide substantial benefit in reducing the spread of drug
resistant parasite genotypes [39].
This study has several limitations. Data sets from several
studies were combined for the purpose of this analysis.
This was a retrospective analysis so inclusion criteria for
the trials were not standardized which resulted in the dif-
ferences in the populations participating in the three sites.
For example, in The Gambia only children were enrolled
while in the other two sites a broader age spectrum was
enrolled. Different covariates were assessed and labora-
tory methods were not standardized between the sites.
Different detection limits for gametocytes affected the
estimated densities and rates of carriage. It is also possible
that the apparent differences in gametocyte carriage rates,
which are dependent on the frequency of observation, are
influenced by these differences in trial conduct. Gameto-
cytes counts were collected at slightly different sampling
schedules and there was a considerable number of miss-
ing values (20–40%) at visits scheduled for all three sites.
The estimates of infectivity are illustrative, being based on
two data-sets which characterized the sigmoid relation-
ship between gametocyte densities and infectivity to an
anopheline vector. This hides considerable inter-individ-
ual variability and the confounding effects of immunity
and other factors. Much more data are needed to charac-
terize and quantify the sources of variance in this assess-
ment and produce more valid assessments necessary to
model the impact of interventions on malaria transmis-
sion.
Conclusion
This study confirms the independent association of
increased rates of gametocyte carriage with anaemia
[29,44], and with treatment with sulphadoxine-pyrimeth-
amine [45,46]. Gametocyte carriage is significantly
reduced by combination treatment with the artemisinin
derivatives (ACT), which were associated with the lowest
rates of gametocyte carriage [11,29]. The large differences
in gametocyte carriage rates between regions with differ-
ent levels of malaria transmission and access to treatment
suggest that drug interventions to prevent transmission
will have different effects in different places. In areas of
high stable transmission, less reduction in transmission
can be expected from effective treatment, with the major
benefit of ACT deployment being reducing the spread of
resistance to non-artemisinin drugs. At low levels of trans-
mission, prompt treatment with gametocytocidal drugs
can have a major effect on the transmission and thus inci-
dence of falciparum malaria.
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